RAPID RECOMMENDATIONS

Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline

OPEN ACCESS

In patients with symptomatic severe aortic stenosis but at lower risk of perioperative death, how do minimally invasive techniques compare with open surgery? Prompted by a recent trial, an expert panel produced these recommendations based on three linked rapid systematic reviews

Per O Vandvik associate professor1 2, Catherine M Otto professor3, Reed A Siemieniuk methodologist4 5, Rodrigo Bagur assistant clinical professor6, Gordon H Guyatt distinguished professor4 7, Lyubov Lytvyn methodologist8, Richard Whitlock associate professor9 10, Trond Vartdal consultant physician11, David Brieger professor12, Bert Aertgeerts professor13, Susanna Price professor14, Farid Foroutan graduate student4 15, Michael Shapiro community representative and senior health informaticist for RTI International16, Ray Mertz community representative17, Frederick A. Spencer professor4 7

1Institute of Health and Society, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; 2Department of Medicine, Innlandet Hospital Trust-division, Gjøvik, Norway; 3Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA 98195; 4Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada L8S 4L8; 5Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 6Division of Cardiology, London Health Sciences Centre and Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada N6A 3K7; 7Department of Medicine, McMaster University, Hamilton, Ontario, Canada L8S 4L8; 8Systematic Overview through advancing Research Technology, Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario Canada M5G 0A4; 9Department of Surgery, McMaster University, Hamilton, Ontario, Canada L8S 4L8; 10Population Health Research Institute, Hamilton, Ontario, Canada L8L 2X2; 11Department of Cardiology, Oslo University Hospital – Rikshospitalet, 0424 Oslo, Norway; 12Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia; 13Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium; 14Royal Brompton Hospital, London SW3 6NP, UK; 15Heart Failure/Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada M5G 2C4; 16Chicago, Illinois, USA; 17London, Ontario, Canada

Corresponding author: P O Vandvik per.vandvik@gmail.com

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Subscribe: http://www.bmj.com/subscribe
Choice of intervention for those with severe aortic stenosis

**Transfemoral TAVI**
Inserting a new valve into the aortic valve's place without open heart surgery. Delivery is through the femoral artery.

**SAVR**
Open-heart surgery, to remove the narrowed aortic valve. Replacement with tissue valve.

### Recommendations

| Population | Favours TAVI | Favours SAVR | Why? |
|------------|--------------|--------------|------|
| Age 85+    | Strong       |              |      |
| Age 75–85  | Weak         |              |      |
| Age 65–75  | Weak         |              |      |
| Age under 65 | Strong    |              |      |

### Key uncertainties

The major uncertainty is the durability of TAVI valves which drives recommendations in favour of SAVR in younger patients.

Choice of intervention for people with severe aortic stenosis who are unsuitable for TAVI by transfemoral approach

**Transapical TAVI**
A more direct delivery of the new valve, through the 6th or 5th intercostal space, into the left ventricle.

**SAVR**
Open-heart surgery, to remove the narrowed aortic valve. Replacement with tissue valve.

### Recommendations

| Population | Favours TAVI | Favours SAVR | Why? |
|------------|--------------|--------------|------|
| All ages   |              | Strong       |      |
A randomised controlled trial of transcatheter aortic valve insertion (TAVI) versus surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis was published in April 2016. The Partner 2 trial included 2032 people at intermediate surgical risk and favoured TAVI over open SAVR at two years for some outcomes. It had the potential to change practice.

Before the availability of TAVI, the only effective treatment for symptomatic severe aortic stenosis was SAVR with mechanical or bioprosthetic valves (fig 1). In practice, patients offered mechanical valves tend to be younger and must accept lifelong anticoagulation. The minimally invasive option, TAVI, was developed for patients who are unfit for surgery, in whom its use is recommended by major US and European guidelines.2-5 Severe aortic stenosis affects approximately 3 in 100 people over the age of 75 years.6 Patients typically experience symptoms of heart failure and reduced quality of life. Without aortic valve replacement, life expectancy is typically 50% at two years, with escalation of heart failure and reduced quality of life.7 These recommendations are for patients with symptoms and severe aortic stenosis; patients without symptoms or with milder disease are not considered here. Box 1 shows the linked articles in this BMJ Rapid Recommendations cluster.

How the recommendations were created

The international expert panel included front line and intervention cardiologists, a heart surgeon, internists, a general practitioner, methodologists, and people with lived experience of the condition (see list of panel members). To avoid bias, we excluded people with a professional, academic, or financial conflict of interest that we judged as excessive (see online methods supplement, competing interests statement, and appendix of interests of the panel members).

The panel followed standards for trustworthy guidelines and used the GRADE methodology to critically appraise the evidence and to create recommendations.6-8 When moving from evidence to recommendations, the panel integrated information on benefits and harms of treatment alternatives, quality of evidence, and values and preferences of patients as well as acceptability, feasibility, and resources (see box 1). Estimates of absolute effects are derived from relative effect estimates from the systematic review coupled with the best population estimates of baseline risks derived from a linked systematic review of observational studies.9 We label recommendations for or against each alternative as either weak or strong (see infographic).

The evidence

A linked systematic review and meta-analysis combines the data from the Partner 2 trial with three other trials (see fig 2). It pools data on 3128 patients with symptomatic severe aortic stenosis at low or moderate risk of perioperative death, typically followed for two years.1-14 Compared with SAVR, transfemoral TAVI reduced mortality and stroke, life threatening bleeds, atrial fibrillation, and acute kidney injury at two years, but increased heart failure, major vascular complications, packemctor insertion, and need for aortic valve reintervention within 2 years (see infographic).16 In contrast, transapical TAVI may increase mortality and stroke compared with the surgical approach. The results for mortality, stroke, and acute kidney injury were based on a subgroup analysis for transfemoral versus transapical approach, deemed credible by the review authors according to specific criteria.15 Estimates of baseline risk for most outcomes came from a linked systematic review on prognosis for patients undergoing SAVR.16 The panel were reasonably confident that the absolute effect sizes for the short term benefit and harm of TAVI and SAVR were true and accurate estimates (that is, overall moderate certainty according to GRADE). But the panel were very uncertain about the long term durability of the valves used in TAVI, particularly with respect to their recommendations in younger patients with a longer predicted life expectancy. The low certainty in the estimated long term re-intervention rate after TAVI of approximately 27 in 100 people reflects an absence of published follow-up studies beyond five years.

The linked systematic review on values and preferences yielded extremely limited evidence to inform the recommendations, particularly their strength.16 There are no studies on patients deciding between TAVI and SAVR, although one study evaluated patient preferences and values when deciding whether to undergo SAVR (versus no surgery).16 17 One study identified multiple biomedical, functional, social, and environmental factors influencing patients’ decisions to undergo assessment for TAVI.18 Overall, there is evidence of variability in individual values and preferences, highlighting the need for shared decision making, particularly for patients aged between 65 and 85 years.

Practical considerations

Perioperative risk is typically assessed by expert cardiovascular teams. Validated risk scores such as the STS-PROM are available online (www.riskcalc.sts). Type of device and TAVI approach may vary: balloon expandable and self expanding devices can be used via
transfemoral, subclavian, direct aortic, transcarotid, or transapical (balloon only) routes.

Fig3 lists issues that may influence a person’s choice of procedure. These are further detailed in MAGICapp within the consultation decision aids that provide all desirable and undesirable consequences of treatment options.

**Costs and resources**

There are no cost effectiveness data for patients at low to intermediate surgical risk considering TAVI versus SAVR. Both procedures are resource demanding and require an experienced cardiovascular team (table 1⇓). In general, TAVI devices are more expensive than surgery, but this extra cost may be partially offset by a slightly shorter hospital stay and less need for post-discharge rehabilitation.

**Future research**

Future recommendations and guidelines would benefit from studies that answer the following questions

- Qualitative or survey study. What are the values and preferences of patients deciding between TAVI and SAVR, particularly with respect to uncertain durability of TAVI devices, the desire to avoid open heart surgery, and post-procedure pain and recovery time?
- What is the durability of the TAVI valves beyond five years?

**Competing interests:** All authors have completed the BMJ Rapid Recommendations interests form. The BMJ Rapid Recommendations team judged that no panel member declared financial, professional, or academic interests that precluded authorship. The declared interests for each panel member are attached. No panel members declared any financial conflicts of interest related to this clinical question, specifically no financial ties to the heart valve industry. D Briger receives personal and institutional research funding from industry, none relevant for TAVI or SAVR (has received funding from Eli Lilly, Astra Zeneca, Sanofi Aventis, Boehringer Ingelhein, Pfizer, Merck Sharp and Dohme, Bristol-Myers Squibb, and Bayer all related to antihypertotic or diabetes therapy). R Whitlock has received funding for consulting with Attircure and Artheneed (both focused on atrial fibrillation management). R Bagur is a primary investigator of a trial on antiocoagulation in atrial fibrillation, sponsored by Bristol-Myers Squibb. R Whitlock performs SAVR. R Bagur performs TAVI. CM Otto has co-chaired the American College of Cardiology guidelines on valvular heart disease, which includes TAVI, and is the UpToDate editor on the same topic. R Whittick is the section lead for the American College of Chest Physicians valve guidelines. S Price is a panel member of the European Cardiology Society guidelines on heart valves. RA Siemieniuk, GH Guyatt, PO Vandvik, CM Otto, R Bagur, F Forouzan, and L Lytvyn participated in writing the complementary systematic reviews that formed the evidence base for this guideline. No panel member has previously formally made statements favouring either option in low or intermediate perioperative risk patients. This article was edited by H MacDonald at The BMJ who had no relevant financial or intellectual interests.

**Box 1: Linked articles in this BMJ Rapid Recommendations cluster**

- Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ. 2016;354:i5130. doi:10.1136/bmj.i5130
- Forouzan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ. 2016;354:i5065. doi:10.1136/bmj.i5065
- Lytvyn L, Guyatt GH, Manja V, et al. Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review. BMJ Open. 2016;6:e014327. doi:10.1136/bmjopen-2016-014327
- Editorial: Siemieniuk RA, Macdonald H, Agoritsas T, Guyatt GH, Vandvik PO. Introduction to BMJ Rapid Recommendations. BMJ. 2016;354:i5191. doi:10.1136/bmj.i5191
- Magic App (www.magicapp.org/public/guideline/aEeKpL)
  - Expanded version of the results with multilayered recommendations, evidence summaries, and decision aids for use on all devices

1 Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investigators. Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Patients. N Engl J Med.2016;374:1609-20. doi:10.1056/NEJMoa1514616.pmed201704294.
2 Nishimura RA, Otto CM, Bonow RO, et al. ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2436-42. doi:10.1161/CIR.0000000000000294.pmed24586982.
3 Vahanian A, Alfieri D, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J.2012;33:2451-96. doi:10.1093/eurheartj/ehs109.pmed2292015.
4 Osnabrugge RL, Mlyttoe D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol.2013;62:1002-12. doi:10.1016/j.jacc.2013.05.019.pmed23727124.
5 Otto CM. Timing of aortic valve surgery. Heart.2009;84:211-8. doi:10.1136/hrt.2008.169620.pmed221346.
6 Lane C, Taichman DB, Murrow C. Trustworthy clinical guidelines. Ann Intern Med.2011;154:774-5. doi:10.7326/0003-4819-154-11-2011060700011pmed22164561.
7 Guyatt GH, Oman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ.2008;336:926-9. doi:10.1136/bmj.39489.470347.dpmid:24094658.
8 Alonso-Coello P, O’Malley AD, Moberg J, et al. GRADE Working Group. GRADE Evidence to Decision (EID) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2. Clinical practice guidelines. BMJ.2016;353:i5209.pmed2705494.
9 Forouzan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ.2016;354:i5065. doi:10.1136/bmj.i5065.
10 Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ.2016;354:i5130. doi:10.1136/bmj.i5130.
11 Nielsen HH, Klaaborg KE, Nissen H, et al. A prospective, randomised trial of transapical transcatheter aortic valve implantation versus surgical aortic valve replacement in elderly patients with aortic stenosis: the STACCATO trial. EuroIntervention.2012;8:383-9.doi:10.4244/EURO08383.pmed2258129.
12 Adams DH, Popma JJ, Reardon MJ, et al. U.S. CoreValve Clinical Investigators. Transcatheter aortic valve replacement with a self-expanding prosthesis. N Engl J Med.2014;370:1790-8. doi:10.1056/NEJMoa1400599.pmed22479837.
13 Søndergaard L, Steinbøch DA, Hienmann N, et al. Two-year outcomes in patients with severe aortic stenosis randomized to transcatheter versus surgical aortic valve replacement: the All-Camer Nordic Aortic Valve Intervention Randomized Clinical Trial.

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Subscribe: http://www.bmj.com/subscribe
How patients were involved in the creation of this article

Two people with lived experience of severe aortic stenosis were full panel members and contributed with their experience and perspectives throughout the Rapid Recommendations process. Initially the community panel members identified pain and recovery time (in addition to already identified outcomes) and practical issues as important for choosing between TAVI and SAVR. They also fully participated in teleconferences and email exchange to discuss the evidence, draft recommendations, and to provide feedback in the creation of this article.
## Table

| Resource                                  | Extent of requirement | TAVI | SAVR |
|-------------------------------------------|-----------------------|------|------|
| Heart team                                | +++                   | +++  | ++   |
| Surgical backup                           | +++                   | N/A  | +++  |
| Cardiac anaesthesia                       | +++                   | +++  | +++  |
| Hybrid suite                              | ++                    | —    | —    |
| Catheterisation laboratory facility       | +++                   | +    | —    |
| Intensive care unit                       | ++                    | +++  | —    |
| Coronary care unit                        | ++                    | +/-  | —    |
| Length of hospital stay (days)†           | 2-5                   | 5-10 | 5-10 |
| Rehabilitation                            | ++                    | +++  | —    |
| Follow-up clinic                          | ++                    | —    | —    |

*Based on panel expert members experience from practice.
†Estimates reflect current practice according to content experts on the panel. Length of stay was considerably longer in the trials (see infographic).
Figures

Fig 1 Flowchart for management of severe aortic stenosis (AS). Coloured boxes represent the recommendations covered by this article. AVR=aortic valve replacement, SAVR=surgical aortic valve replacement, TAVI=transcatheter aortic valve insertion

* Management of this group of patients is outside the scope of the systematic reviews and these recommendations
Patient and trial characteristics

**MEAN AGE**
Approximately 80 years

**GENDER BALANCE**
53% male

**COMORBIDITIES**
Most patients had one or two common medical comorbidities such as:
- Atrial fibrillation 25–45%
- Kidney disease 11–20%
- Diabetes 5–40%
- COPD 3–30%

**DISEASE SEVERITY**
Severe aortic stenosis

**PERIOPERATIVE RISK**
Mean risk of death 3–8%

**PATIENT PARTNERSHIP**
No trials included patients in design or conduct

**FUNDING**
3 of the 4 trials were funded by TAVI manufacturers

---

**Fig 2** Patient and trial characteristics in the four trials of the linked meta-analysis"
### TAVI

- **PROCEDURE**
  - Conscious sedation
  - Catheter-based procedure
  - Under 2 hours
  - Bovine or porcine valve and attached to a flexible, metallic mesh frame

- **RECOVERY**
  - Consider who will help with activities during recovery
  - Avoid strenuous activity
  - Rehabilitation may help recovery
  - Typically 2-5 days in hospital
  - About 1 month to recover
  - Pain from insertion site resolves within a few weeks
  - Data on emotional well-being after TAVI is scant

- **ADVERSE EFFECTS**
  - Endocarditis (about 1% per year)
  - Some symptoms of heart failure can remain after procedure
  - Cognitive decline might occur after valve replacement, but how often is not clear
  - See summary of findings
  - Long-term effects of TAVI are less well known than surgery

- **WORK & EDUCATION**
  - Time until return to work depends on speed of recovery
  - May be 2-6 weeks

- **TRAVEL & DRIVING**
  - Driving may be limited during recovery

- **MEDICATION**
  - Antiplatelet or anticoagulation medication after procedure, as needed
  - Pain medication after procedure, as needed

- **VISITS**
  - Post operative visits are typically within 1-2 months, and then yearly to check that the valve is working

### SAVR

- **PROCEDURE**
  - General anesthesia
  - Major surgery
  - About 3-5 hours
  - Valve replacement uses bovine or porcine tissue
  - The heart may be stopped and supported by a machine

- **RECOVERY**
  - Typically 5-10 days in hospital
  - About 2-3 months to recover
  - About 1 in 4 report pain in the sternum after 1 year, with 1 in 10 with more serious pain
  - Some report mood swings, anxiety, though may also have been present before surgery

- **ADVERSE EFFECTS**
  - Endocarditis (about 1% per year)
  - Repeat procedure if unsuccessful
  - Some symptoms of heart failure can remain after procedure
  - Cognitive decline might occur after valve replacement, but how often is not clear
  - See summary of findings
  - Long-term effects of TAVI are less well known than surgery

- **WORK & EDUCATION**
  - Time until return to work depends on speed of recovery
  - May be 6-8 weeks

- **TRAVEL & DRIVING**
  - Driving is limited for 6 weeks until the sternal bone heals

- **MEDICATION**
  - Antiplatelet or anticoagulation medication after procedure, as needed
  - Pain medication after procedure, as needed

- **VISITS**
  - Post operative visits are typically within 1-2 months, and then yearly to check that the valve is working

---

**Fig 3** Practical considerations that may influence a patient’s choice of procedure. For a complete list, see decision aids in the MAGICapp (www.magicapp.org/public/guideline/aEeKpL)